Skip to content
value.today
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

ANTX
$172 Mmarket cap on Oct 29, 2026-70.2% since Jan 2024
1M
-8.9%
Compare
World rank
#16,823
Revenue
—
For year ending December-2025
Net income
$-35 M
SEC filing
Employees
—

AN2 Therapeutics, Inc. in brief

AN2 Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Menlo Park, California, USA. It was founded in 2017. Its market value was $172 M on 29 October 2026, which makes it the 16,823rd largest listed company in the world and the 3,246th largest in the USA on this site. Eric Easom is its chief executive. Its shares trade under the symbol ANTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc is a biopharmaceutical company develops therapeutics to treat rare, chronic and serious infectious diseases in areas of high unmet medical need. The headquarters is in United States.

AN2 Therapeutics, Inc. timeline

3 events, 2017–2022
  1. 2017
  2. 🏁
    · approximate
    Founded
  3. 2021
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2022
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 28 March 2022; shares registered for exchange trading on 22 March 2022.

Events of AN2 Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$155 M$311 M$466 M$621 M2023202420252026

World rank over time

▲ up 1,569 places since 2022
2022-12-25: #18440#18,44020222023-07-30: #19242#19,24220232024-01-05: #11746#11,74620242026-03-08: #10334#10,33420262026-08-01: #15047#15,04720262026-09-22: #16568#16,56820262026-10-29: #16871#16,8712026

Rank in USA: #3,760 (Dec 2022) · #3,800 (Jul 2023) · #2,419 (Jan 2024) · #2,012 (Mar 2026) · #3,038 (Aug 2026) · #3,172 (Sep 2026) · #3,250 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.2×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-66.3%
Liabilities / assets
14.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-22M—FY21Fiscal year ending Dec 2022: revenue —, net income $-41M—FY22Fiscal year ending Dec 2023: revenue —, net income $-65M—FY23Fiscal year ending Dec 2024: revenue —, net income $-51M—FY24Fiscal year ending Dec 2025: revenue —, net income $-35M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-38M$-35M—
Dec 2024——$-57M$-51M—
Dec 2023——$-70M$-65M—
Dec 2022——$-42M$-41M—
Dec 2021——$-22M$-22M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-30M——$-1.16—
Dec 2024$-49M——$-1.72—
Dec 2023$-53M——$-2.74—
Dec 2022$-33M——$-2.79—
Dec 2021$-20M——$-10.64—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-8M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-8M—Jun ’26Three months to Sep 2026: revenue —, net income $-8M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of AN2 Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-38 M
Net income
$-35 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$62 M
Total liabilities
$9 M
Total equity
$53 M

As of December-2025

Top 88 institutional investors in AN2 Therapeutics, Inc.#

As of Sep 30, 2026
88 institutions held 26.9 M shares (about 70.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in AN2 Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vivo Capital, LLC3,153,6400 (0.00%)8.31%$17 MNov 13, 2026
2Commodore Capital LP2,933,6800 (0.00%)7.73%$16 MNov 16, 2026
3Millennium Management LLC2,476,231+157,539 (+6.79%)6.53%$13 MNov 16, 2026
4BlackRock, Inc.1,771,563+106,069 (+6.37%)4.67%$9 MNov 13, 2026
5Spruce Street Capital LP1,752,011+90,938 (+5.47%)4.62%$9 MNov 13, 2026
6Acorn Capital Advisors, LLC1,300,000New3.43%$7 MNov 16, 2026
7Vanguard Capital Management LLC1,238,7050 (0.00%)3.26%$7 MNov 13, 2026
8Adage Capital Partners GP, L.L.C.1,000,0000 (0.00%)2.64%$5 MNov 16, 2026
9Citadel Advisors LLC984,080+32,083 (+3.37%)2.59%$5 MNov 16, 2026
10Boxer Capital Management, LLC944,035+195,000 (+26.03%)2.49%$5 MNov 16, 2026
11Geode Capital Management, LLC684,122-13,684 (-1.96%)1.80%$4 MNov 6, 2026
12Goldman Sachs Group Inc634,655+546,722 (+621.75%)1.67%$3 MNov 16, 2026
13Tetragon Partners GP Ltd603,424New1.59%$3 MNov 16, 2026
14SummitTX Capital, L.P.597,793+340 (+0.06%)1.58%$3 MNov 16, 2026
15Sio Capital Management, LLC548,103+18,170 (+3.43%)1.44%$3 MNov 16, 2026
16Ameriprise Financial Inc537,225+161 (+0.03%)1.42%$3 MNov 16, 2026
17Ally Bridge Group (NY) LLC526,3150 (0.00%)1.39%$3 MNov 16, 2026
18Woodline Partners LP447,420-12,385 (-2.69%)1.18%$2 MNov 16, 2026
19State Street Corp444,468+132,866 (+42.64%)1.17%$2 MNov 12, 2026
20Stonepine Capital Management, LLC350,877-200,815 (-36.40%)0.92%$2 MNov 13, 2026
21Prosight Management, LP350,877-123,761 (-26.07%)0.92%$2 MNov 13, 2026
22Almitas Capital LLC349,068-1,120,061 (-76.24%)0.92%$2 MNov 17, 2026
23Balyasny Asset Management L.P.287,250-268,777 (-48.34%)0.76%$2 MNov 16, 2026
24BNP Paribas Financial Markets255,878+245,693 (+2412.30%)0.67%$1 MNov 12, 2026
25Seven Fleet Capital Management LP254,309+45,363 (+21.71%)0.67%$1 MNov 16, 2026
Show all 88: investors 26 to 88
Institutional investors 26 to 88 in AN2 Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG251,686+177,600 (+239.72%)0.66%$1 MNov 10, 2026
27Russell Investments Group, Ltd.222,225+220,113 (+10422.02%)0.59%$1 MNov 6, 2026
28Northern Trust Corp209,978-4,943 (-2.30%)0.55%$1 MNov 16, 2026
29Vanguard Fiduciary Trust Co195,856-1,064 (-0.54%)0.52%$1 MNov 13, 2026
30Vanguard Portfolio Management LLC180,924+1,330 (+0.74%)0.48%$1 MNov 13, 2026
31Acuta Capital Partners, LLC142,051New0.37%$1 MNov 16, 2026
32Marshall Wace, LLP106,143New0.28%$1 MNov 13, 2026
33Morgan Stanley81,631+32,252 (+65.32%)0.22%$0 MNov 13, 2026
34Renaissance Technologies LLC80,100-49,600 (-38.24%)0.21%$0 MNov 12, 2026
35Toronto Dominion Bank78,025New0.21%$0 MNov 16, 2026
36Dimensional Fund Advisors LP76,0450 (0.00%)0.20%$0 MNov 4, 2026
37Bank of New York Mellon Corp67,865+189 (+0.28%)0.18%$0 MNov 5, 2026
38Charles Schwab Investment Management Inc64,2200 (0.00%)0.17%$0 MNov 16, 2026
39Bridgeway Capital Management, LLC60,909+1,009 (+1.68%)0.16%$0 MNov 16, 2026
40ADAR1 Capital Management, LLC58,8080 (0.00%)0.15%$0 MNov 16, 2026
41Empowered Funds, LLC58,009New0.15%$0 MNov 13, 2026
42Captrust Financial Advisors41,297+1,132 (+2.82%)0.11%$0 MNov 12, 2026
43Bank Of America Corp /de/40,317-105,486 (-72.35%)0.11%$0 MNov 16, 2026
44Velan Capital Investment Management LP40,0000 (0.00%)0.11%$0 MNov 16, 2026
45Walleye Capital LLC39,972-32,167 (-44.59%)0.11%$0 MNov 13, 2026
46Nuveen, LLC35,423+90 (+0.25%)0.09%$0 MNov 10, 2026
47Rhumbline Advisers32,975+8,633 (+35.47%)0.09%$0 MNov 10, 2026
48American Century Companies Inc25,696New0.07%$0 MNov 12, 2026
49Deutsche Bank AG\22,495-3,343 (-12.94%)0.06%$0 MNov 6, 2026
50Price T Rowe Associates Inc /MD/22,0220 (0.00%)0.06%$0 MNov 16, 2026
51Quadrature Capital Ltd20,735New0.05%$0 MNov 13, 2026
52Gsa Capital Partners LLP20,603New0.05%$0 MNov 16, 2026
53FMR LLC17,753+17,692 (+29003.28%)0.05%$0 MNov 10, 2026
54WINTON GROUP Ltd16,150New0.04%$0 MNov 12, 2026
55Invesco Ltd.13,890+51 (+0.37%)0.04%$0 MNov 12, 2026
56Connor, Clark & Lunn Investment Management Ltd.13,603New0.04%$0 MNov 10, 2026
57Vanguard Global Advisers, LLC13,449+6,115 (+83.38%)0.04%$0 MNov 13, 2026
58Jpmorgan Chase & Co12,981+2,010 (+18.32%)0.03%$0 MNov 12, 2026
59MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.12,856+670 (+5.50%)0.03%$0 MNov 16, 2026
60LPL Financial LLC12,3500 (0.00%)0.03%$0 MNov 6, 2026
61Algert Global LLC11,920New0.03%$0 MNov 17, 2026
62Bronte Capital Management Pty Ltd.10,8950 (0.00%)0.03%$0 MNov 12, 2026
63Barclays PLC10,305+4,814 (+87.67%)0.03%$0 MNov 6, 2026
64Acadian Asset Management LLC10,160New0.03%$0 MNov 9, 2026
65Engineers Gate Manager LP10,143New0.03%$0 MNov 16, 2026
66Mangrove Partners Im, LLC10,139New0.03%$0 MNov 16, 2026
67Police & Firemen's Retirement System of New Jersey8,6150 (0.00%)0.02%$0 MNov 9, 2026
68Royal Bank Of Canada5,544+4,606 (+491.04%)0.01%$0 MNov 16, 2026
69Wells Fargo & Company/mn5,476-16,913 (-75.54%)0.01%$0 MNov 16, 2026
70New York State Common Retirement Fund5,0000 (0.00%)0.01%$0 MNov 17, 2026
71Tower Research Capital LLC (TRC)3,305+1,498 (+82.90%)0.01%$0 MNov 16, 2026
72Legal & General Group Plc2,5760 (0.00%)0.01%$0 MNov 16, 2026
73Ameritas Investment Partners, Inc.2,4020 (0.00%)0.01%$0 MNov 13, 2026
74PNC Financial Services Group, Inc.1,438New0.00%$0 MNov 6, 2026
75Citigroup Inc1,291-10,976 (-89.48%)0.00%$0 MNov 4, 2026
76State of Wyoming603New0.00%$0 MOct 28, 2026
77Sterling Capital Management LLC562+78 (+16.12%)0.00%$0 MOct 22, 2026
78Federated Hermes, Inc.341-108 (-24.05%)0.00%$0 MNov 12, 2026
79Osaic Holdings, Inc.3000 (0.00%)0.00%$0 MNov 12, 2026
80SBI Securities Co., Ltd.2010 (0.00%)0.00%$0 MOct 22, 2026
81GAMMA Investing LLC191New0.00%$0 MOct 8, 2026
82UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC177New0.00%$0 MNov 16, 2026
83Fortitude Family Office, LLC90New0.00%$0 MOct 14, 2026
84Allworth Financial LP38New0.00%$0 MNov 17, 2026
85SJS Investment Consulting Inc.36New0.00%$0 MOct 26, 2026
86Root Financial Partners, LLC24New0.00%$0 MOct 21, 2026
87Caitong International Asset Management Co., Ltd13-261 (-95.26%)0.00%$0 MOct 29, 2026
88Arax Advisory Partners2New0.00%$0 MNov 12, 2026

Mutual funds holding AN2 Therapeutics, Inc.#

53 funds hold shares worth $15 M (about 8.3% of the company). Since their previous reports 47 added shares and 0 sold, buying $9 M net.
Mutual funds holding AN2 Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.853,017$4 M2.2%<0.01%+16%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors603,086$3 M1.6%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.360,114$2 M0.95%<0.01%+43%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC289,229$2 M0.76%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors195,477$1 M0.52%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC122,776$1 M0.32%<0.01%+7.0%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors88,850$0 M0.23%0.03%+67%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.64,220$0 M0.17%<0.01%newJul 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC59,000$0 M0.16%0.19%no changeJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC49,470$0 M0.13%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC48,504$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC35,333$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP35,294$0 M0.09%<0.01%+34%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC32,907$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC29,717$0 M0.08%0.02%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC34,964$0 M0.09%<0.01%+16%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors29,625$0 M0.08%<0.01%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC27,514$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation20,300$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC19,633$0 M0.05%<0.01%+40%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP15,448$0 M0.04%<0.01%+82%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC12,656$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.13,726$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.12,781$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.12,793$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.10,600$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC8,043$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC7,333$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP6,193$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC5,962$0 M0.02%0.01%+52%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS5,831$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC5,803$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.4,147$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.4,037$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP3,416$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC3,536$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC3,466$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,099$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,042$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC2,862$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,600$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,600$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS2,314$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,402$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,112$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,911$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,096$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC986$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC669$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.668$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC574$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC230$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC200$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 53 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at AN2 Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$12 K
1 purchase, 1 insider
Sold, 12 months
$403 K
21 sales, 6 insiders
Net, 12 months
-$391 K
open market only
Insiders on file
24
since
$1.6 M-$4.2 M$0Nov 2023: bought $0 (0 trades), sold $29 K (4 trades)Nov 23Jan 2024: bought $0 (0 trades), sold $4.2 M (12 trades)Aug 2024: bought $1.6 M (1 trades), sold $3.8 M (2 trades)AugNov 2024: bought $397 K (12 trades), sold $0 (0 trades)Dec 2024: bought $87 K (6 trades), sold $0 (0 trades)DecJan 2025: bought $0 (0 trades), sold $20 K (4 trades)May 2025: bought $10 K (1 trades), sold $3.1 M (5 trades)MayJun 2025: bought $11 K (1 trades), sold $0 (0 trades)Nov 2025: bought $0 (0 trades), sold $4 K (2 trades)NovJan 2026: bought $0 (0 trades), sold $46 K (8 trades)Mar 2026: bought $0 (0 trades), sold $347 (1 trades)MarMay 2026: bought $0 (0 trades), sold $1 K (1 trades)Jul 2026: bought $0 (0 trades), sold $25 K (1 trades)JulAug 2026: bought $0 (0 trades), sold $213 K (2 trades)Sep 2026: bought $12 K (1 trades), sold $106 K (7 trades)SepNov 2026: bought $0 (0 trades), sold $12 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
AN2 Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joshua M. EizenSee RemarksSell-2,826$4.220$12 K207,546Form 4
filed Kabeer AzizDirectorGrant or award+2,465——61,571Form 4
filed Patricia A. MartinDirectorGrant or award+389——19,252Form 4
filed Gilbert Lynn MarksDirectorGrant or award+2,283——84,156Form 4
filed Cameron C. Trenor IIIChief Medical OfficerGrant or award+116,667——116,667Form 4
filed Robin Shane ReadnourDirectorSell10b5-1 plan · indirect-523$6.020$3 K557,467Form 4
filed Robin Shane ReadnourDirectorSell10b5-1 plan · indirect-585$6.020$4 K624,765Form 4
filed Robin Shane ReadnourDirectorSell10b5-1 plan · indirect-4,725$6.020$28 K557,990Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: AN2 Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.4 M
8.9% of shares · 9.18 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 2.353-for-1 split

Fails to deliver

  • : 55,333 shares at $4.52
  • : 466 shares at $3.63
  • : 472 shares at $3.55
  • : 2,325 shares at $3.37
  • : 3,427 shares at $4.96

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

AN2 Therapeutics, Inc. scorecard#

Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.2×Price to book 3.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.16 vs -1.72Diluted EPS -1.16 in fiscal 2025 against -1.72 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-52.1%-52.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.9×Current ratio 6.87 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

AN2 Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

AN2 Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Research and development2540552916
General and administrative131415134.7
Operating expenses3857704222
Operating income−38−57−70−42−22
Interest and finance income2.95.5r4.9——
Other non-operating income (expense)0.00.00.0r1.3r−0.0
Income tax00000
Net income including minority interests−35−51−65−41−22
Net income attributable to shareholders−35−51−65−41−22
Earnings per share, basic-1.16-1.72-2.74-2.79-10.64
Earnings per share, diluted-1.16-1.72-2.74-2.79-10.64
Shares, weighted average (basic)303024152.6
Shares, weighted average (diluted)303024152.6
Balance sheet
Cash and cash equivalents2021162712
Short-term investments3862926946
Other current assets1.92.63.22.51.6
Current assets60861119960
Total assets629213910365
Accounts payable3.03.32.72.11.1
Current liabilities8.710147.23.4
Total liabilities8.910147.23.4
Retained earnings−241−206−154−90−47
Shareholders' equity538212595−47
Total liabilities and equity629213910365
Shares outstanding273030192.7
Cash-flow statement
Share-based compensation6.28.38.44.41.0
Cash from operating activities−30−49−53−33−20
Cash from investing activities2855−43−22−50
Shares issued0.10.10.4——
Cash from financing activities0.10.4857079
Change in cash−1.45.7−12158.0
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at AN2 Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9

AN2 Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Unregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreementShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
RestructuringDirectors and officers8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of AN2 Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$40 MPrivate placement after listing$10 to $50 million16equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at AN2 Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-08-07
AN2 Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
AN2 Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How AN2 Therapeutics, Inc. compares in Biotechnology

  • Market cap$172 M · higher than 42% of 726
  • Price / book3.2× · lower than 46% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
AN2 Therapeutics, Inc.🇺🇸$172 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at AN2 Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show AN2 Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about AN2 Therapeutics, Inc.? Suggest a correction